Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
Methods for analysing drug blood levels and searching for markers of drug efficacy and side effects were investigated to establish optimal dosing design methods for nivolumab, a high-cost antibody drug used for lung cancer. The drug blood levels of nivolumab can now be measured in a relatively simple method and samples from patients treated with nivolumab alone can be analysed. Peptides obtained by trypsin digestion of cancer-related proteins were analysed, and it was assessed that it was difficult to obtain markers by the usual method of serum proteomics due to insufficient sensitivity. Since the application for the Grant-in-Aid for Scientific Research for this study, several marker analyses for drug efficacy and side effects have been reported, and the relationship between these markers and blood levels of nivolumab is currently under investigation.
|